Logo

Geneoscopy: Don Hardison

Mar 17, 2021

Geneoscopy has appointed Don Hardison to its strategic advisory board. Hardison has more than 40 years of leadership experience in both emerging and Fortune 500 companies. He most recently served as president and CEO of Biotheranostics, until its acquisition by Hologic in February 2021. Prior to that, Hardison served as president, CEO, and director at Good Start Genetics, and also held the position of president and CEO of Exact Sciences, where he helped oversee the company's initial public offering. 

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.